As a global leader in pain research, our innovators explore and apply the latest science to develop life-changing treatments for millions of patients worldwide. Learn more here…
Grünenthal announces Joint Venture Collaboration with Kyowa Kirin International for established medicines portfolio with sales of ~€200 million.
The transaction combines Grünenthals unrivalled expertise in pain management with Kyowa Kirin’s portfolio of valuable medicines anchored in pain management. Grünenthal intends to acquire the full portfolio at the beginning of 2026.Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio
4,500 dedicated employees – 75 years of experience in developing innovative medicines – a fully integrated setup including R&D and five manufacturing sites.
These are some of the key figures that have helped us become the leading pain management company in Europe and Latin America.For the latest insights into our people, our products and our ambitious plans to move closer to our vision of a worldfreeofpain, check out the... Grünenthal Report 2021/2022
Grünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Make an impact.
Innovate for a world free of pain.
Visit our careers website